Healthy adult
Conditions
Interventions
The subjects ingested a single intake of the active meal, and ingested a single intake of the placebo meal after 7 days, and also ingested a single intake of the blank meal after 7 days.
The subjects
Sponsors
Kao Corporation
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Subjects whose fasting blood glucose levels are ranged to less than 126mg/dl 2) Subjects whose HbA1c levels are ranged to less than 6.2% 3) Subjects whose BMI are from 18.5 kg/m2 to less than 30 kg/m2 4) Subjects who can make self-judgment and are voluntarily giving written informed consent
Exclusion criteria
Exclusion criteria: 1) Subjects who take continuous medical treatment 2) Subjects who are contracting heart disease, liver disease, kidney disease, digestive disease and allergy disease 3) Subjects with smoking habit 4) Subjects who participate in other clinical trials 5) Subjects who are not eligible due to physician`s judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood samples were collected before ingestion and at 0.5, 1, 2, 3 and 4 hours after ingestion. FMD was measured before ingestion and at 1, 2, 3 and 4 hours after ingestion. Urine samples were collected before ingestion and accumulation urine samples were pooled during the postprandial periods for 4 hrs. Primary outcomes are blood glucose and vascular endothelial function | — |
Secondary
| Measure | Time frame |
|---|---|
| Key secondary outcomes are insulin, d-ROMs and urinary 8-OHdG | — |
Countries
Japan
Contacts
Public ContactHiroko Jokura
Kao Corporation R&D -Core Technology- Biological Science Research
Outcome results
None listed